AbbVie: 5 Reasons That Make A Buy Case
by Manika Premsingh
Contributor since 2022 / 2409 Followers
Contributor since 2022 / 2409 Followers
10 months ago
Summary: AbbVie’s weak stock price performance in the past quarter is in no way an
ABBV
AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
by JR Research
Contributor since 2021 / 34453 Followers
Contributor since 2021 / 34453 Followers
11 months ago
Summary: AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024
AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now
by Kody's Dividends
Contributor since 2018 / 8878 Followers
Contributor since 2018 / 8878 Followers
11 months ago
Summary: AbbVie’s recent stock decline is a classic example of how valuation can greatly influence
AbbVie: The Inevitable Is Happening
by ONeil Trader
Contributor since 2012 / 8123 Followers
Contributor since 2012 / 8123 Followers
12 months ago
Summary: AbbVie Inc.’s shares dropped last week due to concerns about the erosion of Humira
Unveiling AbbVie’s Winning Strategy In Pharmaceutical Innovation (Rating Upgrade)
by ALLKA Research
Contributor since 2023 / 395 Followers
Contributor since 2023 / 395 Followers
12 months ago
Summary: On April 26, AbbVie published financial results for the first quarter of 2024, which
AbbVie’s Q1: Positive Surprise
by Jonathan Weber
Contributor since 2014 / 50351 Followers
Contributor since 2014 / 50351 Followers
12 months ago
Summary: AbbVie’s Q1 earnings beat estimates, with a smaller decline in Humira sales than expected.
AbbVie Q1 Earnings Preview: No Repeat Of Last Year’s Q1 Disappointment
by Edmund Ingham
Contributor since 2018 / 11308 Followers
Contributor since 2018 / 11308 Followers
1 year ago
Summary: AbbVie Inc.’s Q1 2024 earnings will be announced next Friday, with Wall Street projecting
AbbVie: Through Humira’s Crisis Towards Solid Growth
by Rafa F. Oliver, CFA
Contributor since 2023 / 359 Followers
Contributor since 2023 / 359 Followers
1 year ago
Summary: AbbVie has successfully managed the patent expiration of its top-selling drug Humira by delaying
AbbVie: Great To Be Proven Wrong – Still Not A Buy
by Juxtaposed Ideas
Contributor since 2022 / 10174 Followers
Contributor since 2022 / 10174 Followers
1 year ago
Summary: ABBV has outperformed expectations, with Humira remaining the market leader with 98% share despite
AbbVie: Bulletproof Fundamentals
by Dair Sansyzbayev
Contributor since 2023 / 6051 Followers
Contributor since 2023 / 6051 Followers
1 year ago
Summary: AbbVie is a profitability superstar with a strong track record of success, generating almost